Author: sugaradmin

Introduction and Objective:IntroductionAdvancements in blood glucose measurement and insulin dosing over the past two decades have improved outcomes for individuals with Type 1 diabetes (T1D). However, chronic kidney disease (CKD) remains a significant management challenge. The frequency of specialist outpatient (OP) appointments could serve as a proxy for disease severity. This study aimed to determine […]

Introduction and Objective: Guidelines recommend GLP-1 receptor agonists (GLP-1-RA) and SGLT2 inhibitors (SGLT2i) for individuals with type 2 diabetes (T2D) at high risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to develop a personalized treatment algorithm to guide the initial decision between these therapies.Methods: Using data from the Diabetes Prospective Follow-up registry (Germany/Austria) we studied […]

Introduction and Objective: Continuous glucose monitoring (CGM) is a diagnostic tool widely used to monitor glucose levels in patients with diabetes and to guide insulin dose adjustments in outpatients. In the critical setting of inpatient care, however, special regulatory requirements on glucose measurements necessitate accuracy of CGM measurements as a prerequisite for its integration into […]

Introduction and Objective: Diabetes mellitus is a common complication after solid organ transplant (SOT). Sodium-glucose cotransporter inhibitors (SGLT2i) have shown significant cardio-renal benefits in people with type 2 diabetes. However, their use in SOT recipients remains underexplored in the existing literature. We aimed to perform a systematic review and meta-analysis to evaluate the efficacy and […]

Introduction and Objective: This study examines the impact of online, virtual patient simulation (VPS)-based continuing medical education (CME) on performance related to diagnosis and management of T2D by diabetologists/endocrinologists (D/Es) and primary care physicians (PCPs).Methods: Intervention was 2 patient scenarios presenting in a VPS. Clinical guidance (CG) based on evidence was provided following each decision, […]

Introduction and Objective: Ketones are energy substrates, serving as a “superfuel” for the heart, skeletal muscle, etc.. Our previous work showed that 3-hour intravenous (IV) exogenous ketones (KE) improved left ventricular function in T2D patients with HFrEF by up to 6%, dose-dependently. However, IV delivery is invasive and impractical for daily use. This study explores […]

Introduction and Objective: Type 2 diabetes (T2D) is marked by impaired insulin secretion and action in metabolic organs like adipose tissue and skeletal muscle. Aberrant gene expression contributes to T2D. Alternative polyadenylation (APA) alters gene expression by producing mRNA isoforms with variable 3’ UTR lengths. The 3’ UTR interacts with trans-factors, affecting mRNA stability, translation, […]

Introduction and Objective: Proximal Intestinal Mucosal Ablation (PIMA) is a new endoscopic procedure to treat type 2 diabetes (T2D). PIMA replicates the metabolic benefits of gastric bypass surgery by ablating up to 75 cm of the post-ampullary intestinal mucosa with radiofrequency vapor ablation (RFVA). Similar technologies, limited to 15cm of duodenal mucosa, have attempted to […]

Introduction and Objective: Type 2 diabetes (T2D) is frequently associated with hepatic complications like fatty liver and fibrosis named Metabolic dysfunction associated steatotic liver disease (MASLD).This study evaluates the demographic profile, Body Mass Index (BMI) and liver health parameters— Fibrosis-4 (FIB-4) score, Controlled Attenuation Parameter (CAP) score and Liver Stiffness Measurement (LSM)Methods: A total of […]

Introduction and Objective: MET-233 is an ultra-long acting (ULA) amylin analog being evaluated in clinical trials for the treatment of obesity. We sought preclinical proof of concept that MET-233, designed to be combined with GLP-1R agonist MET-097, is an effective candidate for obesity treatment.Methods: MET-233 emerged from an amylin analog development program focused on potency, […]